
    
      Phase lb To determine maximal tolerated dose (MTD) and recommended phase ll dose (RP2D) of
      alpelisib in combination with capecitabine regardless of PIK3CA mutation of any solid tumors

      Phase ll To investigate the progression-free survival (PFS)

      Conduct the exploratory biomarker analysis for efficacy and resistance of alpelisib plus
      capecitabine combination (using collected clinical samples)
    
  